AbbVie Inc. (ABBV) Stock Forecast
Data as of Aug 1, 2026Healthcare · Current price $252.68 (-1.85%)
Price Target Range
Consensus Price Target Over Time
Analyst Rating Distribution
Last 3 Months
6-Month Trend
Latest Analyst Forecasts
Price targets issued by Wall Street analysts. Upside calculated against today's price.
| Date | Analyst | Firm | Price Target | Upside |
|---|---|---|---|---|
| Apr 10, 2026 | Vamil Divan | Guggenheim | $249.00 | -1.5% |
| Feb 24, 2026 | Trung Huynh | RBC Capital | $260.00 | +2.9% |
| Feb 4, 2026 | Gavin Clark-Gartner | Evercore ISI | $228.00 | -9.8% |
| Jan 28, 2026 | Asad Haider | Goldman Sachs | $223.00 | -11.7% |
| Jan 15, 2026 | Evan David Seigerman | BMO Capital | $258.00 | +2.1% |
| Nov 5, 2025 | David Amsellem | Piper Sandler | $289.00 | +14.4% |
| Nov 3, 2025 | Gary Nachman | Raymond James | $256.00 | +1.3% |
| Oct 17, 2025 | Gary Nachman | Raymond James | $250.00 | -1.1% |
| Sep 15, 2025 | Carter Gould | Cantor Fitzgerald | $245.00 | -3.0% |
| Feb 3, 2025 | Gary Nachman | Raymond James | $220.00 | -12.9% |
| Feb 3, 2025 | Evan Seigerman | BMO Capital | $215.00 | -14.9% |
| Nov 12, 2024 | Evan David Seigerman | BMO Capital | $208.00 | -17.7% |
| Oct 31, 2024 | Evan David Seigerman | BMO Capital | $228.00 | -9.8% |
| Oct 31, 2024 | Charlie Yang | Bank of America Securities | $210.00 | -16.9% |
| Oct 31, 2024 | Geoff Meacham | Citigroup | $226.00 | -10.6% |
| Oct 18, 2024 | Geoff Meacham | Bank of America Securities | $195.00 | -22.8% |
| Oct 17, 2024 | Courtney Breen | Bernstein | $203.00 | -19.7% |
| Aug 23, 2024 | Christopher Raymond | Raymond James | $209.00 | -17.3% |
| Jul 19, 2024 | Evan Seigerman | BMO Capital | $214.00 | -15.3% |
| Jun 18, 2024 | Christopher Raymond | Raymond James | $190.00 | -24.8% |
Top Analysts Covering ABBV
ABBV vs Sector & Market
| Metric | ABBV | Healthcare Avg | Large Cap Avg |
|---|---|---|---|
| Analyst Rating | 2.11 | 2.25 | 2.42 |
| Analyst Count | 28 | 8 | 19 |
| Target Upside | +10.6% | +16316.2% | +17.1% |
| P/E Ratio | 123.90 | 2.90 | 43.33 |
Revenue Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-12-31 | $66.52B | $67.06B | $67.43B | 22 |
| 2027-03-31 | $15.61B | $15.80B | $16.02B | 6 |
| 2027-06-30 | $17.73B | $17.95B | $18.19B | 6 |
| 2027-09-30 | $18.43B | $18.65B | $18.91B | 6 |
| 2027-12-31 | $18.99B | $19.22B | $19.48B | 6 |
| 2028-03-31 | $17.04B | $17.25B | $17.49B | 6 |
| 2028-06-30 | $19.43B | $19.66B | $19.93B | 5 |
| 2028-09-30 | $19.87B | $20.11B | $20.38B | 5 |
| 2028-12-31 | $20.15B | $20.39B | $20.67B | 6 |
| 2029-12-31 | $80.39B | $81.88B | $82.97B | 23 |
| 2030-12-31 | $82.27B | $83.81B | $84.92B | 15 |
EPS Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-12-31 | $13.92 | $14.12 | $14.63 | 18 |
| 2027-03-31 | $3.18 | $3.23 | $3.28 | 5 |
| 2027-06-30 | $4.03 | $4.09 | $4.16 | 5 |
| 2027-09-30 | $4.13 | $4.19 | $4.27 | 5 |
| 2027-12-31 | $4.23 | $4.30 | $4.37 | 5 |
| 2028-03-31 | $3.32 | $3.37 | $3.43 | 6 |
| 2028-06-30 | $4.46 | $4.53 | $4.61 | 6 |
| 2028-09-30 | $4.24 | $4.31 | $4.39 | 7 |
| 2028-12-31 | $4.34 | $4.41 | $4.49 | 9 |
| 2029-12-31 | $19.12 | $19.58 | $19.92 | 10 |
| 2030-12-31 | $19.67 | $20.15 | $20.50 | 5 |
Frequently Asked Questions
What is the analyst consensus for ABBV?
The consensus among 28 analysts covering AbbVie Inc. (ABBV) is Buy with an average price target of $258.00.
What is the highest price target for ABBV?
The highest price target for ABBV is $289.00, set by David Amsellem at Piper Sandler on 2025-11-05.
What is the lowest price target for ABBV?
The lowest price target for ABBV is $127.00, set by Tim Anderson at Wolfe Research on 2021-05-03.
How many analysts cover ABBV?
28 analysts have issued ratings for AbbVie Inc. in the past 12 months.
Is ABBV a buy or sell right now?
Based on 28 analyst ratings, ABBV has a consensus rating of Buy (2.11/5) with a +10.6% upside to the consensus target of $258.00.
What are the earnings estimates for ABBV?
Analysts estimate ABBV will report EPS of $14.12 for the period ending 2026-12-31, with revenue estimated at $67.06B.
Related Stock Forecasts
Data updated daily. Analyst price targets sourced from public filings and broker reports. Not investment advice.